secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001104659-25-027504
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio FY 2024 net loss $45.4M ($0.60/sh); cash $176.5M, runway to 2027
-------------------------------------------------------------------------

- Cash and cash equivalents $176.5M as of Dec 31, 2024, up from $99.8M at year-end 2023; sufficient to fund operations through 2027.
- Net loss improved to $45.4M ($0.60 per share) from $69.2M ($2.09 per share) in 2023.
- Initiated Phase 2 TibuSURE trial for tibulizumab in systemic sclerosis (SSc) in Dec 2024; Phase 2 HS trial planned for Q2 2025.
- Completed $112.5M private placement in April 2024; also executed warrant exchange and established ATM program in 2024.
- Robert Lisicki appointed CEO in April 2024; Kiran Nistala joined as CMO in Jan 2024; Scientific Advisory Board established June 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465925027504/0001104659-25-027504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465925027504/tm2510115d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-027504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer